Anagenics’ FY2025 Revenue Drops to $5.12M as Losses Hit $1.24M
Anagenics Limited has revealed a significant 52.6% decline in revenue alongside an 83.5% increase in net loss for the financial year ended June 2025, marking a challenging period for the biotech company.
- Revenue fell 52.6% to $5.12 million
- Net loss widened by 83.5% to $1.24 million
- Net tangible assets per share turned negative at -0.03 cent
- Shares on issue increased to 496.3 million
- No dividends declared for FY2025
Financial Performance Overview
Anagenics Limited (ASX, AN1), a player in the biotechnology sector, has reported a challenging financial year for 2025. The company’s revenue from ordinary activities dropped sharply by 52.6% to $5.12 million compared to the previous year. This steep decline signals potential headwinds in sales or operational disruptions that have impacted the company’s top line.
Compounding the revenue decline, Anagenics recorded a net loss after tax attributable to shareholders of $1.24 million, an 83.5% increase in losses compared to the prior year. This widening loss margin highlights the company’s struggle to contain costs or generate sufficient income from its operations during the period.
Balance Sheet and Shareholder Impact
The company’s net tangible asset backing per ordinary security fell from a positive 0.09 cent in June 2024 to a negative 0.03 cent in June 2025. This shift into negative territory suggests a deterioration in the company’s underlying asset value relative to its liabilities, a metric closely watched by investors assessing financial health.
Meanwhile, the number of shares on issue increased to 496.3 million from 461.3 million the previous year, indicating potential capital raising activities or share issuances that may have diluted existing shareholders but provided necessary funding.
Dividend and Audit Notes
Consistent with the financial challenges, Anagenics did not declare or pay any dividends during the year, reflecting a cautious approach to preserving cash amid losses. The company’s consolidated financial statements were audited by William Buck Audit (Vic) Pty Ltd, which issued an unmodified audit opinion, providing assurance on the accuracy and compliance of the reported figures.
Looking Ahead
While the Appendix 4E filing offers a snapshot of Anagenics’ financial performance, it leaves unanswered questions about the drivers behind the revenue decline and loss escalation. Investors will be keen to explore the full 2025 Annual Report for deeper insights into operational challenges, cost management strategies, and the company’s outlook in a competitive biotech landscape.
Bottom Line?
Anagenics faces a pivotal moment as it seeks to reverse declining revenues and stem rising losses in the year ahead.
Questions in the middle?
- What factors contributed most to the sharp revenue decline in FY2025?
- How does Anagenics plan to address its increasing net loss and negative tangible asset backing?
- Will the company pursue further capital raises or strategic partnerships to stabilize its financial position?
